AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1632114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine i.v.
Number of subjects: 12
Study 1632114 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of 0.9% NaCl i.v. (Control)
Number of subjects: 12
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + streptozotocin (Stz)
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + Methyl‐CCNU (MeCCNU)
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU alone
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin alone
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) for bile duct cancer
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + streptozotocin (Stz) for bile duct cancer
Number of subjects: 87
Study 6235908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + Methyl‐CCNU (MeCCNU) for bile duct cancer
Number of subjects: 87
Study 29630791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 238
Study 29630791 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice
Number of subjects: 238
Study 26951644 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus pain advice from an independent investigator
Number of subjects: 280
Study 26951644 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 280
Study 25391190 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk fortified with human milk fortifier (HMF)
Number of subjects: 33
Study 25391190 — intervention group
Group type: COMPARATOR
Intervention: Post discharge formula (PDF)
Number of subjects: 33
Study 22453865 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic drugs (FGAs) - perphenazine and haloperidol
Number of subjects: 84
Study 22453865 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs (SGAs) - olanzapine and clozapine
Number of subjects: 84
Study 22453865 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched for age and gender)
Number of subjects: 84
Study 20490908 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-occupational post-exposure prophylaxis (nPEP)
Number of subjects: 4295
Study 20490908 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-nPEP users)
Number of subjects: 4295
Study 18385918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 0.15 mg
Number of subjects: 168
Study 18385918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 0.4 mg
Number of subjects: 168
Study 18385918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 1 mg
Number of subjects: 168
Study 18385918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 2.5 mg
Number of subjects: 168
Study 18385918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 15999421 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of hyaluronic acid (HA) 5 times daily for 1 week
Number of subjects: 60
Study 15999421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 12198664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily starting one week before transplantation until week 52 after transplantation (group 1)
Number of subjects: 20
Study 12198664 — intervention group
Group type: COMPARATOR
Intervention: No antiviral therapy to HBV (group 2)
Number of subjects: 20
Study 12198664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (group 1)
Number of subjects: 20
Study 9801852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically pamidronate)
Number of subjects: 0
Study 9801852 — intervention group
Group type: COMPARATOR
Intervention: First-generation bisphosphonates (etidronate and clodronate)
Number of subjects: 0
Study 9801852 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation bisphosphonates (pamidronate)
Number of subjects: 0
Study 8657501 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with carnitine
Number of subjects: 15
Study 8657501 — intervention group
Group type: COMPARATOR
Intervention: Normal weight newborns
Number of subjects: 15
Study 2114350 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal tamponade (n = 52)
Number of subjects: 108
Study 2114350 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin/nitroglycerin infusion (n = 56)
Number of subjects: 108
Study 2114350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 108
Study 111704 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine
Number of subjects: 0
Study 111704 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 0
Study 31116172 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patient (VSP) cases
Number of subjects: 14
Study 27878809 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention
Number of subjects: 103
Study 27878809 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (including continued medication)
Number of subjects: 103
Study 25961767 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (74 caregivers)
Number of subjects: 148
Study 25961767 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (74 caregivers)
Number of subjects: 148
Study 25961767 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 148
Study 24001627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic music exercise
Number of subjects: 146
Study 24001627 — intervention group
Group type: COMPARATOR
Intervention: Different music information
Number of subjects: 146
Study 21330095 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methadone (10-45 mg/day as powder dissolved in ethoxydiglycol added to PLO)
Number of subjects: 16
Study 21330095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone (15-40 mg/day)
Number of subjects: 16
Study 21330095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topically administered)
Number of subjects: 16
Study 19297556 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 42
Study 19297556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulse cyclophosphamide (IVCY)
Number of subjects: 42
Study 19297556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 42
Study 17112875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 95
Study 17112875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 95
Study 15025555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125mg day 1, 80mg once daily on days 2 and 3 or 2-5) plus standard therapy (intravenous ondansetron and oral dexamethasone)
Number of subjects: 3
Study 15025555 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy plus placebo
Number of subjects: 3
Study 15025555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard therapy
Number of subjects: 3
Study 11570629 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic electrical stimulation (TES) applied to antagonists of spastic leg muscles
Number of subjects: 12
Study 11570629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TES)
Number of subjects: 12
Study 9592914 — intervention group
Group type: EXPERIMENTAL
Intervention: Patelladyn-bandage
Number of subjects: 25
Study 9592914 — intervention group
Group type: EXPERIMENTAL
Intervention: Kasseler-bandage
Number of subjects: 25
Study 9592914 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Genuplus-bandage
Number of subjects: 25
Study 9592914 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuhit-bandage
Number of subjects: 25
Study 9592914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandages (all types)
Number of subjects: 25
Study 8166188 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 271
Study 8166188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 8166188 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent or recurrent sialidase 8 weeks after treatment
Number of subjects: 271
Study 3285312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 20
Study 3285312 — intervention group
Group type: COMPARATOR
Intervention: Dietary changes (hydrolyzed casein formula or elimination of milk from mothers' diets)
Number of subjects: 20
Study 3285312 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling after reexposure to cow's milk or soy protein
Number of subjects: 20
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Color of tether adjuster casing (black or red)
Number of subjects: 96
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling on tether adjuster casing (labeled with 'Tether: Use for forward‐facing' or unlabeled)
Number of subjects: 96
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage location of tether (bundled in a rubber band on the back of CRS or Velcroed over the forward‐facing belt path)
Number of subjects: 96
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling in vehicle (labeled under head restraint and below anchor or unlabeled)
Number of subjects: 96
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation using lower anchors (LAs)
Number of subjects: 96
Study 31194584 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall installation methods (including seat belt use)
Number of subjects: 96
Study 27838659 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advice and text messaging (SMSalud®)
Number of subjects: 320
Study 27838659 — intervention group
Group type: COMPARATOR
Intervention: Health advice (control group)
Number of subjects: 320
Study 25988461 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (tapering 15-day course: 60 mg for 5 days, 40 mg for 5 days, 20 mg for 5 days; total cumulative dose = 600 mg; n=181)
Number of subjects: 269
Study 25988461 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (n=181)
Number of subjects: 269
Study 25988461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=88)
Number of subjects: 269
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Current light smokers (<15 pack-years)
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed/retired subjects
Number of subjects: 29367
Study 23394461 — intervention group
Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment/premature retirement
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 29367
Study 23394461 — intervention group
Group type: EXPERIMENTAL
Intervention: Current heavy smoking (≥15 pack-years)
Number of subjects: 29367
Study 21426607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented pre-term formula
Number of subjects: 58
Study 21426607 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-term formula
Number of subjects: 58
Study 19466959 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-BPO 2.5% fixed-dose combination gel
Number of subjects: 1670
Study 19466959 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% monotherapy
Number of subjects: 1670
Study 19466959 — intervention group
Group type: COMPARATOR
Intervention: BPO 2.5% monotherapy
Number of subjects: 1670
Study 19466959 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (gel vehicle)
Number of subjects: 1670
Study 19466959 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO
Number of subjects: 1670
Study 16506874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 4479
Study 16506874 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (subgroup with greatest propensity)
Number of subjects: 4479
Study 16506874 — intervention group
Group type: COMPARATOR
Intervention: No physical therapy (control group)
Number of subjects: 4479
Study 15541156 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered oral health questionnaire
Number of subjects: 453
Study 15541156 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview by research officer or dentist
Number of subjects: 453
Study 15541156 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of questionnaire administration
Number of subjects: 453
Study 11903420 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 9
Study 11903420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9577377 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification Refractory Mutation System (ARMS) test
Number of subjects: 46
Study 7944471 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 53
Study 7944471 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP
Number of subjects: 53
Study 7944471 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 3588562 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (dietary counseling to restrict sodium intake)
Number of subjects: 1001
Study 3588562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 1001
Study 28840750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 10 mg by intra-articular injection
Number of subjects: 56
Study 28840750 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) 25 mg by intra-articular injection
Number of subjects: 56
Study 28840750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) and Hyaluronic acid (HA)
Number of subjects: 56
Study 27917921 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement data recorded during ECG interpretation
Number of subjects: 31
Study 27917921 — intervention group
Group type: COMPARATOR
Intervention: Permutation test comparing gaze shifts
Number of subjects: 31
Study 24850106 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant provocation during interlaminar epidural steroid injection
Number of subjects: 48
Study 24850106 — intervention group
Group type: COMPARATOR
Intervention: Discordant provocation during interlaminar epidural steroid injection
Number of subjects: 48
Study 24359174 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs) - clomipramine and paroxetine
Number of subjects: 36
Study 24359174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20966692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postplacental IUD insertion
Number of subjects: 102
Study 20966692 — intervention group
Group type: COMPARATOR
Intervention: Delayed IUD insertion
Number of subjects: 102
Study 18626126 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized brochure (IB)
Number of subjects: 100
Study 18626126 — intervention group
Group type: COMPARATOR
Intervention: General brochure (GB)
Number of subjects: 100
Study 12131867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (400 mg x 2 daily for 15 days, then 400 mg daily for 20 days)
Number of subjects: 32
Study 12131867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 12131867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 32
Study 12131867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 9690761 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ribotyping
Number of subjects: 0
Study 9690761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field gel electrophoresis (PFGE) assay
Number of subjects: 0
Study 9690761 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐ribotyping
Number of subjects: 0
Study 9690761 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of RFLP data
Number of subjects: 0
Study 8024131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling rate of 0.7 ± 0.1 degrees C/h
Number of subjects: 16
Study 8024131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling rate of 1.7 ± 0.4 degrees C/h
Number of subjects: 16
Study 2685958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (MaxEPA)
Number of subjects: 40
Study 2685958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive and corn oil)
Number of subjects: 40
Study 949899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg b.d. for 3 days
Number of subjects: 21
Study 949899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28556062 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus plantarum, Lactobacillus brevis, Pediococcus acidilactici), 2 oral tablets per day for 6 weeks
Number of subjects: 59
Study 28556062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same tablets without live bacteria), 2 oral tablets per day for 6 weeks
Number of subjects: 59
Study 28556062 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 59
Study 26846042 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate ProClinical A1500 Power Toothbrush
Number of subjects: 79
Study 26846042 — intervention group
Group type: COMPARATOR
Intervention: Manual flat-trim toothbrush (Oral-B Indicator)
Number of subjects: 79
Study 22700844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 7250
Study 22700844 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 7250
Study 21624729 — intervention group
Group type: EXPERIMENTAL
Intervention: In Our Own Voice intervention
Number of subjects: 156
Study 19784509 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.5% ropivacaine and PCA with 0.2% ropivacaine + fentanyl 3 microg.mL‐1
Number of subjects: 41
Study 19784509 — intervention group
Group type: COMPARATOR
Intervention: Continuous lumbar plexus block with 0.5% ropivacaine and PCA with 0.2% ropivacaine
Number of subjects: 41
Study 19784509 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 41
Study 19784509 — intervention group
Group type: COMPARATOR
Intervention: Lumbar plexus block
Number of subjects: 41
Study 19784509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 41
Study 16720930 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy (CEOP-Bleo: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses)
Number of subjects: 102
Study 16720930 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 102
Study 15567627 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intervention on A tests (arm I)
Number of subjects: 0
Study 15567627 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intervention on B tests (arm II)
Number of subjects: 0
Study 15567627 — intervention group
Group type: COMPARATOR
Intervention: Control arm without any intervention on B tests (arm III)
Number of subjects: 0
Study 11743058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (reducing sedentary behavior and increasing physical activity)
Number of subjects: 67
Study 11743058 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase intervention (increasing physical activity)
Number of subjects: 67
Study 11743058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment
Number of subjects: 67
Study 11743058 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of targeted child weight loss
Number of subjects: 67
Study 11743058 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of sibling weight loss
Number of subjects: 67
Study 9449222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis nutritional formula (UCNF)
Number of subjects: 30
Study 9449222 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 30
Study 8498653 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion flow rate of 2.4 L.min‐1 x m‐2 (Group I)
Number of subjects: 20
Study 8498653 — intervention group
Group type: COMPARATOR
Intervention: Perfusion flow rate of 1.2 L.min‐1 x m‐2 (Group II)
Number of subjects: 20
Study 8498653 — intervention group
Group type: EXPERIMENTAL
Intervention: High perfusion flow (Group I)
Number of subjects: 20
Study 31878131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (14% CHO, 58% fat, 28% protein) for 4 weeks
Number of subjects: 19
Study 29277060 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMLS + PTS
Number of subjects: 22
Study 29277060 — intervention group
Group type: COMPARATOR
Intervention: SEMLS no PTS
Number of subjects: 22
Study 27551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with darunavir/ritonavir (DRV/r‐MT arm)
Number of subjects: 43
Study 27551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with lopinavir/ritonavir (LPV/r‐MT arm)
Number of subjects: 43
Study 27551725 — intervention group
Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (cART arm)
Number of subjects: 43
Study 25367545 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening via tablet computer (with option for audio assist)
Number of subjects: 0
Study 25367545 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interview conducted by a fully bilingual/bicultural researcher
Number of subjects: 0
Study 25367545 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening
Number of subjects: 0
Study 25367545 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face screening
Number of subjects: 0